Diltiazem
As of the edition of 20 October 2026, Diltiazem is a small molecule: marketed, first approved in 1979 (FR); acts on CACNA1C, CACNA1D and CACNA1F and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1995
- Kind
- Small molecule
- Brand name
- Cardizem
- First approved
- 2 May 1979 (FR)
- Approvals on record
- 66 in 4 regions
- Holder of the most recent approval
- Hq Specialty Pharma; 8 holders in all
- Registered trials
- 67, 7 stopped early
- Disease areas
- Heart and blood vessels; Digestive system; Infections; Cancer; Lungs and airways; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
8 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product8 company-target rows are on route B because of Diltiazem.
See the 8 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 4 | 1 | 3 |
| Phase 1 | 33 | 25 | 1 | 2 |
| Phase 2 | 4 | 1 | 1 | 1 |
| Phase 3 | 9 | 5 | 2 | 0 |
| Phase 4 | 13 | 7 | 1 | 1 |
| All trials | 67 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sanofi | Later holder and Earlier holder | 1982 to now |
| Merck & Co. | Later holder and Lead sponsor of trials | 1996 to now |
| Bausch Health | Acquired holder | 2005 to now |
| AbbVie | Acquired holder | 2016 to now |
| Exela Pharma Sciences | Later holder | 2021 to now |
| Hq Specialty Pharma | Later holder | 2025 to now |